Glomerulonephritis, IGA clinical trials

The registry lists 275 studies for Glomerulonephritis, IGA across more than 10 countries. 107 are recruiting or about to start. 239 of them are mainly about Glomerulonephritis, IGA (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Glomerulonephritis, IGA studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 94
Recruiting: 67
Not yet recruiting: 33
Status unknown: 29
Active, not recruiting: 21
Terminated: 16

Phase

Phase 2: 83
Phase 3: 52
Phase 4: 32
Phase 1: 25
Early Phase 1: 12

Where

China: 127
United States: 72
United Kingdom: 38
Australia: 34
Spain: 32
France: 31

Who runs them

Novartis Pharmaceuticals (18) · Guangdong Provincial People's Hospital (7) · Sun Yat-sen University (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · Travere Therapeutics, Inc. (5) · Chengdu Suncadia Medicine Co., Ltd. (5) · Peking University First Hospital (5) · The Children's Hospital of Zhejiang University School of Medicine (5)

What is being tested here

Drugs under test in Glomerulonephritis, IGA studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Telitacicept	4	4	8
Atrasentan	3	3	6
Iptacopan	3	3	5
Prednisolone	3	2	5
Mycophenolic Acid	2	2	11
Sibeprenlimab	2	3	5
TACI receptor-IgG Fc fragment fusion protein	2	1	5
Sparsentan	2	1	5
Povetacicept	2	3	4
Zigakibart	2	2	4

Drug classes tested here Endothelin receptor antagonists 6 open · Corticosteroids 4 open · Angiotensin receptor blockers (ARBs) 3 open · Antimetabolites 3

Coming up

30phase 3 studies under way

32studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria · Phase 3 · Biocity Biopharmaceutics Co., Ltd.
May 2027A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) · Phase 3 · Biogen
Jun 2027Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis · Phase 3 · Guixia Ding
Aug 2027A Study of Zigakibart in Adults With IgA Nephropathy · Phase 3 · Novartis Pharmaceuticals
Oct 2027A Trial of HRS-5965 Capsule in Primary IgA Nephropathy · Phase 3 · Chengdu Suncadia Medicine Co., Ltd.
Nov 2026IgA Nephropathy Biomarkers Evaluation Study (INTEREST) · Sun Yat-sen University
Dec 2026A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants · Triastek, lnc.
Dec 2026The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy · Keda Lu
Dec 2026Efficacy and Safety of Telitacicept in IgAN · Ruijin Hospital
Dec 2026A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

Who these studies take

Of the 67 Glomerulonephritis, IGA studies recruiting now, 39 (58%) set no upper age limit and 23 (34%) stop at 75 or younger. 20 (30%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (7%) take healthy volunteers.

Recruiting studies that take each age, of 67
Age	Women	Men
10	16 (24%)	16 (24%)
18	66 (99%)	66 (99%)
30	62 (93%)	62 (93%)
40	62 (93%)	62 (93%)
50	61 (91%)	61 (91%)
65	59 (88%)	59 (88%)
75	54 (81%)	54 (81%)
85	43 (64%)	43 (64%)

Across all 275 studies, recruiting or not: 48% stop at 75 or younger and 25% at 65; 18% take children; <1% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glomerulonephritis, IGA studies take

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	11 mo4–13 · 22 studies	—	—
Phase 2	33 mo17–50 · 41 studies	—	—
Phase 3	55 mo39–70 · 26 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Show 3 more

A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Oct 22, 2026NCT07889362
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeOct 22, 2026NCT07890909
IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyOct 21, 2026NCT07886476

Studies

Recruiting first, then most recently updated. Showing 50 of 275. Browse all 275 → or search them.